Mansukh Mandaviya city New Delhi India Chad covid-19 vaccine Fighting Mansukh Mandaviya city New Delhi India Chad

Bharat Biotech’s intranasal covid-19 vaccine gets DCGI nod for emergency use

Reading now: 645

Last month, Bharat Biotech had said that its intra nasal covid-19 vaccine (BBV154) was safe, well-tolerated, and immunogenic in subjects in controlled clinical trials for the vaccine as a primary dose and a heterologous booster dose.

NEW DELHI: Bharat Biotech’s intranasal covid vaccine on Tuesday received the Drugs Controller General of India (DCGI)approval for restricted emergency use on those above 18 years of age, Union health minister Mansukh Mandaviya said. “Big Boost to India’s Fight Against COVID-19!

Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation," Mandaviya said in a post on Twitter. “This step will further strengthen our collective fight against the pandemic.

India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji’s leadership.

The website is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News